Talking Biotech with Dr. Kevin Folta A Non-Profit Biotech Model; Therapies for Rare Diseases - Dr. Ashley Winslow
Sep 9, 2023
Dr. Ashley Winslow, CEO/CSO of Odylia Therapeutics, discusses a novel non-profit model for addressing rare diseases and the approaches being designed for two rare genetic eye diseases. Topics include the challenges of developing therapies for rare diseases, the founding of a nonprofit biotech company for rare disease research, gene therapy solutions for eye disorders, and the potential of gene therapy for treating Usher syndrome.
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7
Introduction
00:00 • 2min
Founding a Nonprofit Biotech Company for Rare Disease Research
02:08 • 22min
Challenges in a Non-Profit Biotech Company and the Journey of Dr. Ashley Winslow
24:36 • 2min
Gene Therapy Solutions for Eye Disorders: Advantages and Access
26:47 • 4min
Gene Therapy for LCA 6
30:38 • 10min
Usher syndrome and gene therapy for rare diseases
40:20 • 6min
Connecting with Odelia: Website, Social Media, and the Odelia Library
45:59 • 3min